BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/15/2020 12:32:18 PM | Browse: 996 | Download: 1419
 |
Received |
|
2019-03-29 01:49 |
|
Peer-Review Started |
|
2019-04-03 08:28 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2019-11-11 21:28 |
|
Revised |
|
2019-11-28 06:15 |
|
Second Decision |
|
2019-12-13 11:27 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-12-15 05:53 |
|
Articles in Press |
|
2019-12-15 05:53 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-12-20 01:42 |
|
Publish the Manuscript Online |
|
2020-02-15 12:32 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Panagiotis Sarantis, Evangelos Koustas, Adriana Papadimitropoulou, Athanasios G Papavassiliou and Michalis V Karamouzis |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michalis V Karamouzis, MD, PhD, Associate Professor, Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75, M. Asias Street, Athens 11527, Greece. mkaramouz@med.uoa.gr |
| Key Words |
Pancreatic ductal adenocarcinoma; Tumor microenvironment; Immunotherapy; Gemcitabine; Treatment; Cancer stem cells |
| Core Tip |
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies. Treatments such as surgery, radiation, and chemotherapy have limited efficacy due to the extensive heterogeneity of genetic mutations and the dense stromal environment, among other causes. In recent years, immunotherapy has been successfully applied in the treatment of various types of cancers, and immunotherapy combined with the above treatments could create more favorable conditions for the fight against PDAC. |
| Publish Date |
2020-02-15 12:32 |
| Citation |
Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 2020; 12(2): 173-181 |
| URL |
https://www.wjgnet.com/1948-5204/full/v12/i2/173.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v12.i2.173 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
